Carbonyl reductase 1 as a novel target of (2)-epigallocatechin gallate against hepatocellular carcinoma

Weixue Huang, Liya Ding, Qiang Huang, Hairong Hu, Shan Liu, Xianmei Yang, Xiaohui Hu, Yongjun Dang, Suqin Shen, Jie Li, Xiaona Ji, Songmin Jiang, Jun O. Liu, Long Yu

Research output: Contribution to journalArticle

Abstract

Human carbonyl reductase 1 (CBR1) converts the antitumor drug and anthracycline daunorubicin (DNR) into the alcohol metabolite daunorubicinol (DNROL) with significantly reduced antitumor activity and cardiotoxicity, and this limits the clinical use of DNR. Inhibition of CBR1 can thus increase the efficacy and decrease the toxicity of DNR. Here we report that (2)-epigallocatechin gallate (EGCG) from green tea is a promising inhibitor of CBR1. EGCG directly interacts with CBR1 and acts as a noncompetitive inhibitor with respect to the cofactor reduced nicotinamide adenine dinucleotide phosphate and the substrate isatin. The inhibition is dependent on the pH, and the gallate moiety of EGCG is required for activity. Molecular modeling has revealed that EGCG occupies the active site of CBR1. Furthermore, EGCG specifically enhanced the antitumor activity of DNR against hepatocellular carcinoma SMMC7721 cells expressing high levels of CBR1 and corresponding xenografts. We also demonstrated that EGCG could overcome the resistance to DNR by Hep3B cells stably expressing CBR1 but not by RNA interference of CBR1-HepG2 cells. The level of the metabolite DNROL was negatively correlated with that of EGCG in the cell extracts. Finally, EGCG decreased the cardiotoxicity of DNR in a human carcinoma xenograft model with both SMMC7721 and Hep3B cells in mice. Conclusion: These results strongly suggest that EGCG can inhibit CBR1 activity and enhance the effectiveness and decrease the cardiotoxicity of the anticancer drug DNR. These findings also indicate that a combination of EGCG and DNR might represent a novel approach for hepatocellular carcinoma therapy or chemoprevention.

Original languageEnglish (US)
Pages (from-to)703-714
Number of pages12
JournalHepatology
Volume52
Issue number2
DOIs
StatePublished - Aug 1 2010

ASJC Scopus subject areas

  • Hepatology

Fingerprint Dive into the research topics of 'Carbonyl reductase 1 as a novel target of (2)-epigallocatechin gallate against hepatocellular carcinoma'. Together they form a unique fingerprint.

  • Cite this

    Huang, W., Ding, L., Huang, Q., Hu, H., Liu, S., Yang, X., Hu, X., Dang, Y., Shen, S., Li, J., Ji, X., Jiang, S., Liu, J. O., & Yu, L. (2010). Carbonyl reductase 1 as a novel target of (2)-epigallocatechin gallate against hepatocellular carcinoma. Hepatology, 52(2), 703-714. https://doi.org/10.1002/hep.23723